Background: Patients with cancer pain with initially adequate analgesia under oral
sustained-release opioid medication may suffer from persisting pain exacerbations …

Background: In a multicenter study, 28 patients with cancer pain and insufficient pain relief
with analgesic treatment according to step II of the guidelines of the World Health …

Background Pain is one of the most common concomitant symptoms among cancer patients.
Pharmacologic agents are regarded as a cornerstone of cancer pain management.'Dose …

Adequate and rapid pain control is one of the main goals of cancer pain treatment. The
objective of this study was to assess the effect and tolerability of oral normal-release …

BACKGROUND Cancer pain emergencies presenting with severe excruciating pain require
a rapid application of powerful analgesic strategies. The aim of the current study was to …

Breakthrough pain is normally severe in intensity and has a rapid onset. The availability of
supplemental doses of opioids (rescue medication) in addition to the continuous analgesic …

The dose, efficacy, and side effects of continuous intravenous infusion (CIVI) of morphine
were compared with continuous subcutaneous infusion (CSCI) of morphine in patients with …

Objectives To evaluate whether the current European Association for Palliative Care
recommendation regarding the starting dose of 5 mg of normal-release morphine (NRM) …

BACKGROUND: While opioids in increasing doses may produce adverse effects, the same
adverse effects may be associated with poor pain control. Moreover, in the clinical setting …

This randomized controlled trial compared intravenous route with oral route for initial dose
titration of morphine in 62 patients with end-stage cancer and severe pain. Patients in the …